Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer
Season 4, Episode 44, Mar 29, 2021, 08:00 PM
Share
Subscribe
Dr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.